odronextamab
regeneron
['dlbcl', 'lymsm', 'elm-2']
elm-2 interim results #17icml:
-140 pts with r/r dlbcl (2+ lot)
- orr 49%, 48% if car exposed
- mpfs only 4.4 mos, mdor 10 mod
- 5 gr5 aes (mostly infections), less high grade crs with step up dosing
it's the bite era for #lymsm! 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈